Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


National Drug Schedules: Final Recommendations for fluticasone propionate nasal spray

The interim recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on December 9, 2019 that:

  • Fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing no more than 360 metered sprays - be granted Schedule III status.
  • Fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing more than 360 metered sprays -  be granted Schedule II status

were finalized effective January 20, 2020. Final approval of the interim recommendations was made by NAPRA’s Board of Directors. In this case, NAPRA did not receive any comments during the 30-day review period. The National Drug Schedules will be revised accordingly.

Date: